Literature DB >> 23605806

Mathematical model approach to describe tumour response in mice after vaccine administration and its applicability to immune-stimulatory cytokine-based strategies.

Zinnia P Parra-Guillen1, Pedro Berraondo, Emmanuel Grenier, Benjamin Ribba, Iñaki F Troconiz.   

Abstract

Immunotherapy is a growing therapeutic strategy in oncology based on the stimulation of innate and adaptive immune systems to induce the death of tumour cells. In this paper, we have developed a population semi-mechanistic model able to characterize the mechanisms implied in tumour growth dynamic after the administration of CyaA-E7, a vaccine able to target antigen to dendritic cells, thus triggering a potent immune response. The mathematical model developed presented the following main components: (1) tumour progression in the animals without treatment was described with a linear model, (2) vaccine effects were modelled assuming that vaccine triggers a non-instantaneous immune response inducing cell death. Delayed response was described with a series of two transit compartments, (3) a resistance effect decreasing vaccine efficiency was also incorporated through a regulator compartment dependent upon tumour size, and (4) a mixture model at the level of the elimination of the induced signal vaccine (k 2) to model tumour relapse after treatment, observed in a small percentage of animals (15.6%). The proposed model structure was successfully applied to describe antitumor effect of IL-12, suggesting its applicability to different immune-stimulatory therapies. In addition, a simulation exercise to evaluate in silico the impact on tumour size of possible combination therapies has been shown. This type of mathematical approaches may be helpful to maximize the information obtained from experiments in mice, reducing the number of animals and the cost of developing new antitumor immunotherapies.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23605806      PMCID: PMC3691429          DOI: 10.1208/s12248-013-9483-5

Source DB:  PubMed          Journal:  AAPS J        ISSN: 1550-7416            Impact factor:   4.009


  47 in total

1.  Ways to fit a PK model with some data below the quantification limit.

Authors:  S L Beal
Journal:  J Pharmacokinet Pharmacodyn       Date:  2001-10       Impact factor: 2.745

2.  Predicting the course of Gompertzian growth.

Authors:  L Norton; R Simon; H D Brereton; A E Bogden
Journal:  Nature       Date:  1976-12-09       Impact factor: 49.962

3.  PsN-Toolkit--a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM.

Authors:  Lars Lindbom; Pontus Pihlgren; E Niclas Jonsson; Niclas Jonsson
Journal:  Comput Methods Programs Biomed       Date:  2005-09       Impact factor: 5.428

4.  A Gompertzian model of human breast cancer growth.

Authors:  L Norton
Journal:  Cancer Res       Date:  1988-12-15       Impact factor: 12.701

5.  A validated mathematical model of cell-mediated immune response to tumor growth.

Authors:  Lisette G de Pillis; Ami E Radunskaya; Charles L Wiseman
Journal:  Cancer Res       Date:  2005-09-01       Impact factor: 12.701

6.  Comparison of the Akaike Information Criterion, the Schwarz criterion and the F test as guides to model selection.

Authors:  T M Ludden; S L Beal; L B Sheiner
Journal:  J Pharmacokinet Biopharm       Date:  1994-10

7.  Eradication of established tumors by vaccination with recombinant Bordetella pertussis adenylate cyclase carrying the human papillomavirus 16 E7 oncoprotein.

Authors:  Xavier Préville; Daniel Ladant; Benedikt Timmerman; Claude Leclerc
Journal:  Cancer Res       Date:  2005-01-15       Impact factor: 12.701

8.  Cancer immunotherapy: moving beyond current vaccines.

Authors:  Steven A Rosenberg; James C Yang; Nicholas P Restifo
Journal:  Nat Med       Date:  2004-09       Impact factor: 53.440

9.  Modeling immunotherapy of the tumor-immune interaction.

Authors:  D Kirschner; J C Panetta
Journal:  J Math Biol       Date:  1998-09       Impact factor: 2.259

10.  Predictive pharmacokinetic-pharmacodynamic modeling of tumor growth kinetics in xenograft models after administration of anticancer agents.

Authors:  Monica Simeoni; Paolo Magni; Cristiano Cammia; Giuseppe De Nicolao; Valter Croci; Enrico Pesenti; Massimiliano Germani; Italo Poggesi; Maurizio Rocchetti
Journal:  Cancer Res       Date:  2004-02-01       Impact factor: 12.701

View more
  10 in total

1.  Improvement of Parameter Estimations in Tumor Growth Inhibition Models on Xenografted Animals: Handling Sacrifice Censoring and Error Caused by Experimental Measurement on Larger Tumor Sizes.

Authors:  Philippe B Pierrillas; Michel Tod; Magali Amiel; Marylore Chenel; Emilie Henin
Journal:  AAPS J       Date:  2016-06-21       Impact factor: 4.009

Review 2.  Importance of Feedback and Feedforward Loops to Adaptive Immune Response Modeling.

Authors:  Anisur Rahman; Abhinav Tiwari; Jatin Narula; Timothy Hickling
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2018-09-30

Review 3.  Quantitative Mechanistic Modeling in Support of Pharmacological Therapeutics Development in Immuno-Oncology.

Authors:  Kirill Peskov; Ivan Azarov; Lulu Chu; Veronika Voronova; Yuri Kosinsky; Gabriel Helmlinger
Journal:  Front Immunol       Date:  2019-04-30       Impact factor: 7.561

4.  Engineered 3D Model of Cancer Stem Cell Enrichment and Chemoresistance.

Authors:  Maria R Ward Rashidi; Pooja Mehta; Michael Bregenzer; Shreya Raghavan; Elyse M Fleck; Eric N Horst; Zainab Harissa; Visweswaran Ravikumar; Samuel Brady; Andrea Bild; Arvind Rao; Ronald J Buckanovich; Geeta Mehta
Journal:  Neoplasia       Date:  2019-07-09       Impact factor: 5.715

Review 5.  Quantitative Systems Pharmacology: An Exemplar Model-Building Workflow With Applications in Cardiovascular, Metabolic, and Oncology Drug Development.

Authors:  Gabriel Helmlinger; Victor Sokolov; Kirill Peskov; Karen M Hallow; Yuri Kosinsky; Veronika Voronova; Lulu Chu; Tatiana Yakovleva; Ivan Azarov; Daniel Kaschek; Artem Dolgun; Henning Schmidt; David W Boulton; Robert C Penland
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2019-06-11

6.  Modulation of intratumoural myeloid cells, the hallmark of the anti-tumour efficacy induced by a triple combination: tumour-associated peptide, TLR-3 ligand and α-PD-1.

Authors:  Pedro Berraondo; María J Garrido; Sara Zalba; Virginia Belsúe; Brian Topp; Dinesh de Alwis; Maite Alvarez; Iñaki F Trocóniz
Journal:  Br J Cancer       Date:  2021-02-03       Impact factor: 7.640

7.  Challenges and Opportunities for Quantitative Clinical Pharmacology in Cancer Immunotherapy: Something Old, Something New, Something Borrowed, and Something Blue.

Authors:  M Stroh; D J Carlile; C-C Li; J Wagg; B Ribba; S Ramanujan; J Jin; J Xu; J-E Charoin; Z-X Xhu; P N Morcos; J D Davis; A Phipps
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2015-09-11

8.  A review of mixed-effects models of tumor growth and effects of anticancer drug treatment used in population analysis.

Authors:  B Ribba; N H Holford; P Magni; I Trocóniz; I Gueorguieva; P Girard; C Sarr; M Elishmereni; C Kloft; L E Friberg
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2014-05-07

9.  Radiation and PD-(L)1 treatment combinations: immune response and dose optimization via a predictive systems model.

Authors:  Yuri Kosinsky; Simon J Dovedi; Kirill Peskov; Veronika Voronova; Lulu Chu; Helen Tomkinson; Nidal Al-Huniti; Donald R Stanski; Gabriel Helmlinger
Journal:  J Immunother Cancer       Date:  2018-02-27       Impact factor: 13.751

10.  Multivariate analysis of cytokine profiles in pregnancy complications.

Authors:  Fawaz Azizieh; Kamaludin Dingle; Raj Raghupathy; Kjell Johnson; Jacob VanderPlas; Ali Ansari
Journal:  Am J Reprod Immunol       Date:  2018-02-15       Impact factor: 3.886

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.